Podcasts about keytruda

Moderna stock surged over 160% after their personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, reported a successful trial for melanoma. But after the COVID-19 vaccine debacle, can mRNA technology be trusted? Salty Cracker joins Dr. Drew LIVE to discuss the new mRNA cancer treatment, ex Dr. Fauci adviser David Morens pleading guilty to conspiracy, the now-over-$900k GoFundMe for accused murderer Lindsay Clancy (allegedly benefiting her parents), and Roysha / Royce White's WNBA draft bid. Salty Cracker is an uncensored clown world commentator known for breaking the Left with satire, shame, and ridicule. He is active on Rumble as TheSaltyCracker. Follow at https://x.com/saltycracker9 「 SUPPORT OUR SPONSORS 」 • BIOPRO - BioPro+® is a natural formula of growth factors and peptides that support how you look, feel & perform. Learn more at ⁠⁠⁠https://drdrew.com/biopro⁠⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • CHAPTER - For free and unbiased Medicare help, dial (218) 521-2472 to speak with my trusted partner, Chapter, or go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://askchapter.org/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapter and its affiliates are not connected with or endorsed by any government entity or the federal Medicare program. Chapter Advisory, LLC represents Medicare Advantage HMO, PPO, and PFFS organizations and stand alone prescription drug plans that have a Medicare contract. Enrollment depends on the plan's contract renewal. While we have a database of every Medicare plan nationwide and can help you to search among all plans, we have contracts with many but not all plans. As a result, we do not offer every plan available in your area. Currently we represent 50 organizations which offer 18,160 products nationwide. We search and recommend all plans, even those we don't directly offer. You can contact a licensed Chapter agent to find out the number of products available in your specific area. Please contact Medicare.gov, 1-800-Medicare, or your local State Health Insurance Program (SHIP) to get information on all of your options. 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Neuroscientist and educator Jared Cooney Horvath testified before the Senate earlier this year on the impacts of classroom technology. Horvath shares his thoughts on screen time and education.Drug manufacturers Moderna and Merck say a personalized mRNA cancer vaccine plus a drug called Keytruda reduced the return and spread of melanoma in high-risk patients. Dr. Jon LaPook and trial researcher Dr. Janice Mehnert have more information.Neuroscientist and educator Jared Cooney Horvath testified before the Senate earlier this year on the impacts of classroom technology. Horvath shares his thoughts on screen time and education.For America's 250th birthday, USAA unveiled The National Military Monument in Washington, D.C., a living tribute to the more than 41 million veterans who have served the U.S. USAA Senior Vice President Rob Braggs shares that the monument will stay open through Nov. 12. Visit https://monument250.usaa360.com/ for more information. (Sponsored by USAA)Students nationwide are grappling with a new reality -- AI-generated pornography, sometimes featuring themselves or someone they know. CBS News found more than a dozen AI "nudify" apps easily accessible in app stores, some without age restrictions. Jo Ling Kent has more.The NFL is launching a new "celly" campaign to honor the tradition of touchdown celebration dances in the end zone. Jason Allen joins the Houston Texans at their training facility to learn more.

Digital Content Editor, Barbara Friedman, shared her top three stories trending online. Views and News with Clarence Ford is the mid-morning show on CapeTalk. This 3-hour-long programme shares and reflects a broad array of perspectives. It is inspirational, passionate and positive. Host Clarence Ford’s gentle curiosity and dapper demeanour leave listeners feeling motivated and empowered. Known for his love of jazz and golf, Clarrie covers a range of themes including relationships, heritage and philosophy. Popular segments include Barbs’ Wire at 9:30 am (Mon-Thurs) and The Naked Scientist at 9:30 on Fridays. Thank you for listening to a podcast from Views & News with Clarence Ford Listen live on Primedia+ weekdays between 09:00 and 12:00 (SA Time) to Views and News with Clarence Ford broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/erjiQj2 or find all the catch-up podcasts here https://buff.ly/BdpaXRn Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Moderna and Merck just posted the first successful late-stage trial of a personalized mRNA cancer vaccine, intismeran paired with Keytruda, cutting the return and spread of high-risk melanoma, and Erick Erickson spends the hour singing the praises of Big Pharma and taking apart the conspiracy that drug companies are hiding the cure for cancer. He […]

Plus: Target's second-quarter sales suggest the retailer's turnaround is working. And Cantor Fitzgerald plans to give its hedge-fund clients access to Kalshi's prediction markets. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shares of Moderna and Merck are surging on positive results from a Phase 3 trial of a groundbreaking cancer treatment. After a decade in development, individualized mRNA “vaccines” and established cancer treatment Keytruda result in reduced risk of recurrence or death. Moderna CEO Stephane Bancel and Merck Research Laboratories president Dr. Dean Li discuss this pivotal moment in medicine and how it fits into the long term visions for both Merck and Moderna. CEO of design and coding platform Figma Dylan Field discusses his company's wild year as a public company and building public trust in AI. Plus, it was primary night for Democrats in Florida, investors are scrutinizing revenues from Anthropic and OpenAI, and shares of Unitree are surging in Shanghai, presenting a potential challenge to U.S.-based humanoid robotics.    Stephane Bancel & Dr. Dean Li - 15:13 Dylan Field - 33:35   In this episode: Dylan Field, @zoink Becky Quick, @BeckyQuick Andrew Ross Sorkin, @andrewrsorkin Katie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest scientific advancements, regulatory milestones, and strategic business maneuvers shaping the industry. One of the standout developments comes from Otsuka with their drug Voyxact, which has shown promising results in stabilizing kidney function decline in patients with immunoglobulin A nephropathy (IgAN). In a Phase 3 trial, patients exhibited kidney function comparable to that of healthy adults. IgAN is a challenging autoimmune condition often leading to end-stage renal disease. This advancement, leveraging a monoclonal antibody to target specific pathways, could mark a new era in managing this chronic kidney disease. In oncology, Jiangsu Alphamab Biopharmaceuticals has been making waves through strategic collaborations, securing deals worth $125 million upfront and potential milestone payments reaching over $2 billion. Their focus on developing antibody-drug conjugates (ADCs) using AI and machine learning underscores the promise of precision oncology. ADCs marry the targeting precision of antibodies with potent anti-cancer drugs, highlighting robust investment and confidence in these cutting-edge therapies. Merck & Co. continues to expand its financial outlook, driven by the success of its flagship drugs like Keytruda. This monoclonal antibody remains pivotal in cancer immunotherapy, while drugs like Winrevair and Lipfendra are broadening Merck's reach into cardiovascular health. This growth trajectory reflects a strategic push toward diversifying product lines and leveraging breakthrough therapies to maintain strong financial performance. Additionally, Merck's $10.8 billion acquisition of Prometheus Biosciences aims to expand their therapeutic portfolio with targeted biologics. Although mid-stage trials showed mixed results for their anti-TL1A antibody therapy, such acquisitions are pivotal in addressing unmet medical needs. On the regulatory side, Sanofi's MenQuadfi vaccine has achieved EU approval for use in infants as young as six weeks. This approval enhances preventive measures against invasive meningococcal disease in vulnerable populations, representing a significant public health advancement. In research methodologies, Sethera Therapeutics' collaboration with Receptor.AI is notable. By integrating AI-driven platforms for polymacrocyclic peptide discovery aimed at hard-to-drug targets, they're paving the way for overcoming traditional drug discovery challenges through computational tools. However, not all news is about progress. Jazz Pharmaceuticals faced a setback by withdrawing its label indication for Zepzelca after failing Phase 3 trials for small-cell lung cancer. This underscores the inherent risks in clinical development pathways. From a financial standpoint, BioNTech has adjusted its 2025 sales forecast downward due to waning global demand for COVID-19 vaccines—a reflection of the volatile vaccine markets post-pandemic peaks. Meanwhile, Pfizer's discontinuation of its Phase 2 GIPR antagonist for obesity illustrates strategic pivots within R&D pipelines as companies reassess priorities based on trial outcomes and market potential. Recent corporate strategies include Pfizer's ambitious cost-saving plan totaling $9.7 billion through 2029. Amid economic pressures and patent expirations looming on key products like Eliquis, Pfizer is optimizing operations to stay competitive. Speculation around a possible merger between Bristol Myers Squibb (BMS) and AstraZeneca has stirred interest. With both facing patent cliffs, this merger could rejuvenate portfolios—though the strategic benefits for AstraZeneca are still debated. On the technological front, advancements in cellular therapies promise to revolutionize medicine production at the cellular level, potentially enhancing patient outcomes through more personalized treatments. The regulatory landscape is also evolving. There's a growing call for streamlining Investigational New Drug applications under the FDA's Trialblazer initiative—crucial for accelerating clinical trials and bringing innovative therapies to market swiftly. Finally, initiatives such as Boston Scientific's restructuring efforts highlight challenges within the medical device sector as companies adapt to shifting market dynamics. Overall, these developments underscore an industry in motion where innovation and adaptation are key to navigating complex landscapes and advancing patient care globally. As we look ahead, these trends will likely continue shaping the future of pharmaceuticals and biotech in profound ways.Support the show

Lucie Low is the Chief Science Officer of Axiom Space, a prominent space company developing its own space station and conducting private astronaut missions, among other activities. Lucie and I talk about what interesting use cases are for in-space research and manufacturing, what remains to be done to make it a large-scale reality, and other related topics. Enjoy!

In today's episode, we spoke with Sara M. Tolaney, MD, MPH, about the FDA approval of sacituzumab govitecan plus pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-authorized test. Dr Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancers and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in Boston, Massachusetts.This regulatory decision was backed by findings from the phase 3 ASCENT-04/KEYNOTE-D19 trial (NCT05382286), in which the median progression-free survival among patients in the sacituzumab govitecan arm was 11.2 months (95% CI, 9.3-16.7) vs 7.8 months (95% CI, 7.3-9.3) among patients who received physician's choice of chemotherapy plus pembrolizumab (HR, 0.65; 95% CI, 0.51-0.84; P = .0009).In our exclusive interview, Dr Tolaney highlighted the significance of this approval, key data from ASCENT-04, and how the TNBC paradigm is shifting to accommodate this new regimen.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

Charles Schwab's Rachel Dashiell highlights rising market breadth, with the S&P 500 (SPX) equal weight index and NYSE advance-decline line hitting new highs despite pressure on the broader index. She points to rotation into healthcare, financials and industrials, while flagging a potential double bottom in Capital One (COF) and a bullish breakout setup in Merck (MRK) supported by Keytruda news.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the dynamic shifts and breakthroughs shaping the industry, from major acquisitions to groundbreaking scientific advancements. Merck KGaA has made headlines with its bold $11.3 billion acquisition of Bio-Techne Corporation. This marks Merck's most significant deal since purchasing Sigma-Aldrich in 2015, reinforcing its strategic focus on expanding its life sciences tools portfolio. The acquisition aims to accelerate innovation in drug development and diagnostics, highlighting Merck's commitment to enhancing its capabilities in biotechnology under the leadership of CEO Kai Beckmann. Such strategic moves underscore a broader trend towards bolstering biotech portfolios through mergers and acquisitions as companies aim to remain competitive in an ever-evolving market landscape. In regulatory news, the FDA has approved a pioneering combination therapy involving Gilead's Trodelvy and Merck & Co.'s Keytruda for the first-line treatment of triple-negative breast cancer (TNBC). This aggressive cancer subtype has historically had limited treatment options, making this approval particularly significant. The combination therapy leverages an antibody-drug conjugate targeting Trop-2 alongside a PD-1 inhibitor, offering a promising new strategy that could substantially improve patient survival outcomes. This development also highlights the growing role of antibody-drug conjugates in oncology, illustrating how innovative therapeutic combinations can enhance treatment efficacy. Meanwhile, Pfizer's Ibrance has received FDA approval for label expansion to treat HR-positive, HER2-positive metastatic breast cancer. As a CDK4/6 inhibitor crucial in cell cycle regulation, Ibrance's expanded use reflects ongoing advancements in targeted therapies that personalize cancer treatment based on specific molecular characteristics. Such expansions demonstrate the importance of continuous clinical evaluation and regulatory engagement in extending the lifecycle and applications of existing drugs. Ionis Pharmaceuticals has gained FDA approval for Tryngolza for severe hypertriglyceridemia, marking a significant milestone for antisense oligonucleotide therapies. By targeting apolipoprotein C-III, Tryngolza offers a novel approach to managing metabolic conditions linked to pancreatitis risks. This approval underscores the growing importance of antisense technology in addressing complex lipid disorders and highlights Ionis' strategic efforts to expand market reach through global partnerships. On the business development front, Boehringer Ingelheim's partnership with Immunai aims to leverage artificial intelligence in T-cell target discovery for cancer and autoimmune diseases. The integration of AI/ML technologies into drug discovery processes is increasingly seen as essential for enhancing precision and efficiency. This collaboration reflects an industry-wide shift towards embracing technology to improve research and development outcomes. In clinical trials, Otsuka's centanafadine shows promise for adults with ADHD and comorbid anxiety following successful Phase 3b trials. As a small molecule reuptake inhibitor, centanafadine could provide dual therapeutic benefits for patients with these overlapping conditions. Such developments highlight ongoing innovation in neuropsychiatric treatments aimed at addressing mental health conditions with greater precision. Financially, Oblenio Bio's $62 million Series B funding round will support advancing its tri-specific autoimmune T-cell engager into trials, potentially offering new solutions for autoimmune diseases through innovative immunotherapy approaches. These financial movements illustrate how companies are strategically positioning themselves to capitalize on emerging therapeutic opportunities. Amid these developments, regulatory dynamics continue to evolve, as seen with the FDA's pilot program aimed at streamlining drug approval processes. Initiatives like these are pivotal in restoring confidence in regulatory frameworks while adapting to new scientific insights and technological advancements. Overall, these developments underscore the pharmaceutical and biotech sectors' dynamic nature, characterized by strategic collaborations, regulatory milestones, and innovative treatment options poised to enhance patient care and strengthen drug development pipelines. The ongoing integration of cutting-edge technologies such as AI signifies an evolution towards more personalized and efficient healthcare solutions. Thank you for tuning into Pharma Daily, where we bring you the latest insights from the forefront of pharmaceutical and biotech innovation. Join us next time as we continue to explore the trends shaping the future of healthcare globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of impactful developments shaping the future of medical innovation and patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates, and strategic collaborations. One of the more controversial events involves the retraction of a high-profile study in Nature Medicine. This study initially suggested that the timing of PD-1 inhibitor administration had significant impacts on survival rates for non-small cell lung cancer patients. Early-day administration was linked to improved outcomes compared to later in the day. However, after a four-month investigation, concerns over methodological validity led to its retraction. This incident serves as a stark reminder of the necessity for rigorous peer review and transparency in clinical research, which are essential for influencing treatment protocols effectively. In industry news, Eli Lilly has entered into a major $1.9 billion partnership with Abbisko Therapeutics to harness Abbisko's drug discovery capabilities, particularly in oncology. This collaboration highlights an increasing trend where Western pharmaceutical companies team up with Asian biotech firms to accelerate drug development and tap into innovative therapeutic platforms. Eli Lilly is also recalibrating its strategy for launching its oral obesity treatment, Foundayo, in Europe, as it navigates the complexities introduced by the Most Favored Nation pricing agreement with the U.S. This underscores a broader challenge within the industry: balancing pricing regulations with expanding access through digital health channels like telehealth. ADC Therapeutics is taking steps to address safety concerns surrounding its antibody-drug conjugate, Zynlonta, by reducing its workforce by 17%. This strategic realignment demonstrates the delicate balance companies must maintain between advancing promising therapies and ensuring patient safety through vigilant clinical oversight. On the regulatory front, Incyte's decision to drop its lawsuit against CMS over drug classification issues involving its JAK inhibitor Opzelura highlights ongoing negotiations between pharmaceutical companies and regulatory bodies. These classifications have direct implications for market access and reimbursement strategies. Shifting focus to infrastructure, Advancell's move to establish its U.S. headquarters near Boston for radiopharmaceutical production underscores an emphasis on localizing drug manufacturing facilities to enhance supply chain resilience. This decision aligns with broader efforts to support domestic clinical trials for innovative therapies targeting prostate cancer. In terms of technological innovation, Novartis has invested $105 million upfront in Antares Therapeutics to target historically undruggable cancer proteins through small molecule development. This move reflects an industry-wide push towards exploiting cutting-edge technologies like AI-driven drug discovery to meet unmet medical needs in oncology. Precision medicine continues to gain traction, exemplified by Abbott's partnership with AlzPath to develop blood-based diagnostic tests for Alzheimer's disease. Collaborations such as these are pivotal in enhancing early diagnosis and personalized treatment approaches for neurodegenerative disorders. Meanwhile, the industry's financial dynamics continue to evolve with significant fundraising activities. Serapha Bio's public debut through a reverse merger with Boundless Bio raised $230 million, highlighting a growing trend of utilizing reverse mergers as a pathway to public markets. This financial boost comes alongside their licensing of a gene editing technology from China, underscoring the global nature of biotech collaborations. In oncology, Eli Lilly's extended partnership with Abbisko Therapeutics underscores the ongoing commitment to precision medicine, aiming to harness small molecule innovations targeting specific cancer pathways. Concurrently, the European Medicines Agency approved Astellas' Padcev combined with Merck & Co.'s Keytruda for muscle-invasive bladder cancer treatment based on promising Phase 3 results. Ophthalmology research is also seeing substantial investment with Ollin Biosciences raising $330 million in Series B funding aimed at developing therapies that challenge existing treatments like Vabysmo for eye diseases. Such investments indicate strong confidence in novel therapies that could redefine standards in treating conditions like wet age-related macular degeneration. In conclusion, these developments reflect a vibrant biotech and pharma landscape characterized by strategic partnerships, innovative financing mechanisms, and regulatory milestones that collectively drive forward scientific progress and enhance therapeutic options available worldwide. As these sectors continue to evolve, integrating cutting-edge technologies like gene editing and precision oncology will be pivotal in shaping healthcare delivery's future trajectory while improving patient outcomes globally.Support the show

"There's no reason why I should be able to do an infusion for 50% of the cost of what it's currently being allowed at. We've seen allowed amounts between $57,000 and $80,000 for Keytruda. I typically can have that in the home at $29,000."My guest this week is Jake Velie, CEO and co-founder of National Integrative Health (NIH). After spending the first half of his career in the clinical "meat grinder" of value-based care on the provider side, Jake realized the only way to truly fix the system was to control the dollars on the commercial plan side. Today, NIH acts as the ultimate watchdog and independent pharmacy solution for self-funded employers, actively managing J-codes, specialty drugs, and clinical coordination.In this episode, we unpack the exorbitant markups hospitals charge for infusions and how NIH has spent years building a 50-state network to redirect patients to safe, comfortable, and massively discounted at-home infusion care. Jake also breaks down the brutal reality of GLP-1 adherence, why his team refuses to fill 90-day prescriptions for weight-loss drugs, how they enforce formularies to switch patients from expensive biologics like Humira to low-cost biosimilars like Yusimry, and the absolute truth about the safety of international drug sourcing.If you want to know how to stop the bleeding on your pharmacy and medical claims while actually improving the white-glove customer service your employees receive, this is a masterclass in specialty cost containment.Thank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit https://www.paretohealth.com/fully-insured-vs-self-funding-with-paretohealth-spencer-podcast/?utm_source=youtube&utm_medium=referral&utm_campaign=SelfFundedwSpencer to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Moving Keytruda to the Home Setting (00:01:47) Defining True Value-Based Care (00:03:20) The Genesis of NIH and Leaving the Provider "Meat Grinder" (00:07:01) Building a 50-State Home Infusion Network (00:09:22) Why Specialty Meds Drive 90% of Pharmacy Spend (00:14:53) Demystifying J-Codes and Q-Codes (00:17:01) Exorbitant Hospital Markups and Hidden Fees (00:24:59) The Mechanics of Redirection: Mandatory vs. Voluntary (00:30:27) Coordinating Carve-Outs with Stop-Loss Carriers (00:34:08) Enforcing Formularies: Converting Humira to Yusimry (00:41:12) The Reality of International Sourcing and the FDA (00:47:35) Managing GLP-1s and the Danger of 90-Day Fills (00:51:48) The Ideal Employer Profile for NIH (00:58:04) Overcoming Healthcare's Terrible Customer Service (01:02:05) The Future: Oncology, Cell, and Gene TherapiesKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

"There's no reason why I should be able to do an infusion for 50% of the cost of what it's currently being allowed at. We've seen allowed amounts between $57,000 and $80,000 for Keytruda. I typically can have that in the home at $29,000."My guest this week is Jake Velie, CEO and co-founder of National Integrative Health (NIH). After spending the first half of his career in the clinical "meat grinder" of value-based care on the provider side, Jake realized the only way to truly fix the system was to control the dollars on the commercial plan side. Today, NIH acts as the ultimate watchdog and independent pharmacy solution for self-funded employers, actively managing J-codes, specialty drugs, and clinical coordination.In this episode, we unpack the exorbitant markups hospitals charge for infusions and how NIH has spent years building a 50-state network to redirect patients to safe, comfortable, and massively discounted at-home infusion care. Jake also breaks down the brutal reality of GLP-1 adherence, why his team refuses to fill 90-day prescriptions for weight-loss drugs, how they enforce formularies to switch patients from expensive biologics like Humira to low-cost biosimilars like Yusimry, and the absolute truth about the safety of international drug sourcing.If you want to know how to stop the bleeding on your pharmacy and medical claims while actually improving the white-glove customer service your employees receive, this is a masterclass in specialty cost containment.Thank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit https://www.paretohealth.com/fully-insured-vs-self-funding-with-paretohealth-spencer-podcast/?utm_source=youtube&utm_medium=referral&utm_campaign=SelfFundedwSpencer to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Moving Keytruda to the Home Setting (00:01:47) Defining True Value-Based Care (00:03:20) The Genesis of NIH and Leaving the Provider "Meat Grinder" (00:07:01) Building a 50-State Home Infusion Network (00:09:22) Why Specialty Meds Drive 90% of Pharmacy Spend (00:14:53) Demystifying J-Codes and Q-Codes (00:17:01) Exorbitant Hospital Markups and Hidden Fees (00:24:59) The Mechanics of Redirection: Mandatory vs. Voluntary (00:30:27) Coordinating Carve-Outs with Stop-Loss Carriers (00:34:08) Enforcing Formularies: Converting Humira to Yusimry (00:41:12) The Reality of International Sourcing and the FDA (00:47:35) Managing GLP-1s and the Danger of 90-Day Fills (00:51:48) The Ideal Employer Profile for NIH (00:58:04) Overcoming Healthcare's Terrible Customer Service (01:02:05) The Future: Oncology, Cell, and Gene TherapiesKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.Their conversation focused on the rapidly evolving treatment paradigm for triple-negative breast cancer (TNBC), the integration of metabolic health strategies, the clinical emergence of antibody-drug conjugates (ADCs) in the frontline metastatic setting, and the management of treatment-related toxicities.Drs Park and Iyengar examined data from the phase 3 TROPION-Breast02 trial (NCT05374512), which evaluated first-line datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) in patients with PD-L1-negative metastatic TNBC. The trial demonstrated improvements in both progression-free survival and overall survival (OS) with Dato-DXd compared with standard chemotherapy. Notably, the experts also highlighted a remarkable ORR with Dato-DXd, showing that the ADC may be a robust treatment option for symptomatic patients or those experiencing rapid progression.They also discussed individualizing treatment between Dato-DXd and sacituzumab govitecan-hziy (Trodelvy) based on biomarker status, dosing schedules, and distinct toxicity profiles. Furthermore, the experts emphasized the importance of proactive management of unique ADC-associated toxicities. For Dato-DXd, they recommended prophylactic dexamethasone mouthwash and lubricating eye drops to mitigate mucositis and corneal surface events. For sacituzumab govitecan, they noted the necessity of growth factor support for neutropenia and loperamide for diarrhea.Regarding early-stage disease, they reaffirmed the phase 3 KEYNOTE-522 trial (NCT03036488) regimen of pembrolizumab (Keytruda) plus chemotherapy as the standard of care, with adjuvant escalation using capecitabine or PARP inhibitors for patients with residual disease.Drs Park and Iyengar concluded by spotlighting metabolic health interventions for patients with breast cancer. Although GLP-1 receptor agonists show promise in breast cancer survivors, Dr Iyengar cautioned against their initiation during active neoadjuvant immunotherapy due to their potential effects on pathologic complete response rates. He advocated for lifestyle interventions, including resistance training and a plant-forward, high-protein diet, to maintain lean muscle mass and improve OS outcomes.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.  They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.    Episode Timestamps:  00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.  00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.  00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.  00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.  00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.  00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.  00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.  00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit    Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray;  LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/    Keep up with David Radwaner;  LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/    Keep up with Tom Brockbank;  LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/      Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis was joined by Meghan E. Shea, MD, an attending medical oncologist and ambulatory medical director and disease program leader for medical oncology at Beth Israel Deaconess Medical Center in Boston. Together, they explored the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and antibody-drug conjugates (ADCs) across disease settings.Dr Shea opened by addressing the epidemiology of cervical cancer, noting that despite decades of progress, rates are now plateauing and rising among women under 50 years of age. She identified 3 interrelated drivers of this trend: declining rates of routine gynecologic screening, inconsistent uptake of human papillomavirus (HPV) vaccination, and persistent high-risk HPV infections, particularly HPV 16 and 18, which are responsible for most cases. The conversation then turned to the effect of immunotherapy on cervical cancer treatment. Dr Shea traced the evolution of pembrolizumab (Keytruda) from its initial 2018 approval as a single agent in recurrent/metastatic disease to its more recent integration into the frontline setting. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated that adding pembrolizumab to standard weekly cisplatin-based chemoradiation significantly improved outcomes for patients with locally advanced disease. Although responses to immunotherapy, when they occur, are often durable, Dr Shea acknowledged that response rates remain lower than anticipated for a virally driven malignancy, underscoring the need for novel combinations and a deeper understanding of resistance mechanisms. Drs Matulonis and Shea both agreed that immunotherapy combined with ADCs represents one of the most compelling directions for the field, with phase 2 data for sacituzumab tirumotecan plus pembrolizumab generating interest ahead of anticipated phase 3 results.On the ADC front, Dr Shea reviewed the 2 agents in this class that are currently FDA-approved for cervical cancer. Tisotumab vedotin-tftv (Tivdak) offers the advantage of biomarker-independent use, though its requirement for ophthalmologic monitoring at every treatment visit creates real-world access challenges outside major academic centers. Trastuzumab deruxtecan-nxki (Enhertu), approved in the HER2 immunohistochemistry 3+ setting based in part on the results of the phase 2 DESTINY-PanTumor02 trial (NCT04482309), has generated robust response rates but is most likely to benefit patients with adenocarcinoma. Dr Shea also highlighted additional targets under investigation, including Trop-2, Nectin-4, and B7-H4, with multiple phase 3 trials ongoing in both the frontline and recurrent settings.The discussion closed with a look at the locally advanced disease landscape, where the NRG Oncology cooperative group is conducting a phase 3 trial to evaluate whether integrating the neoadjuvant carboplatin/paclitaxel regimen from the INTERLACE trial (NCT01566240) with the pembrolizumab-based regimen from KEYNOTE-A18 can further improve outcomes and reduce the morbidity associated with brachytherapy. Dr Shea expressed optimism about this question, citing preliminary experience suggesting that neoadjuvant chemotherapy may reduce the need for invasive radiation techniques.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the U.S. FDA's recent approval of Gilead Sciences' Hepcludex (bulevirtide) for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA-approved therapy targeting chronic hepatitis D virus infection—a niche condition with limited treatment options. Similarly, Pfizer's Braftovi (encorafenib) is expanding its global reach beyond U.S. borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost-cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus Holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is Niowave's $75 million investment in a radiopharmaceutical isotope plant in Michigan, set to produce actinium-225 by 2028—an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the FDA despite leadership changes. Initiatives like the Commissioner's National Priority Voucher program illustrate regulatory bodies' commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine Skyvaricella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R&D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limmatech Biologics, and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases—a field that has gained focus post-COVID-19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a Phase 2 trial of a lipid-lowering gene editor from Verve Therapeutics, showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics—an exciting breakthrough suggesting substantial potential for gene-editing technologies addressing genetic disorders like high cholesterol. In oncology, AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple-negative breast cancer as a first-line treatment. This antibody-drug conjugate targets Trop2, demonstrating the potential of targeted therapy in difficult-to-treat cancers. Kura Oncology's combination therapy featuring darlifarnib and Krazati showed up to a 69% response rate in KRAS G12C-mutated solid tumors during Phase 1 trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase 3 success with bariatric surgery-like outcomes. The drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity—a condition linked with numerous comorbidities. Moderna's mFlusiva is poised for an FDA advisory committee review as an influenza preventative for older adults—an extension of Moderna's mRNA technology initially used against COVID-19. Collectively, these developments highlight an industry leveraging cutting-edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio—a move aligned with global immunization strategies. This follows hiring Peter Marks from the FDA, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by IDEA Pharma as a leader in pharmaceutical innovation—a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies. Across oncology landscapes highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and Akeso's potential Keytruda rivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles—the current environment promises significant advancements offering new hope while demanding strategic agility within healthcare sectors globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest happenings shaping the landscape of this dynamic industry. The pharmaceutical and biotech sectors are navigating a complex landscape replete with scientific advancements and regulatory challenges. A significant legal development comes from Takeda, which faces an $885 million verdict in a landmark pay-for-delay antitrust case. This ruling highlights the intense scrutiny of pharmaceutical companies over antitrust regulations, with potential implications for drug pricing strategies and industry practices. The possibility of tripling damages under these laws could set a precedent affecting future business operations, as Takeda plans to appeal, underscoring the high stakes involved in such litigation. Meanwhile, on the regulatory front, the White House's decision to include 600 generic medications in the TrumpRx purchasing portal marks a strategic effort to improve drug affordability. While its overall impact remains uncertain, this initiative aims to bridge gaps in medication accessibility for cost-sensitive populations. Similarly, Roche's licensing agreement with the Medicines Patent Pool to allow generic versions of Xofluza in 129 developing countries is a noteworthy step towards enhancing global access to essential medicines. These efforts underscore ongoing attempts to address affordability and accessibility concerns on a global scale. In clinical developments, UCB's Bimzelx has shown promising results against AbbVie's Skyrizi in treating psoriatic arthritis, demonstrating a statistically significant reduction in disease activity compared to Skyrizi in a Phase 3b trial. With nearly half of the patients showing improved outcomes at week 16, Bimzelx is poised to become a competitive therapeutic option, potentially redefining treatment protocols for psoriatic arthritis. Novartis's termination of its contract with Chinese CDMO Porton Pharma Solutions due to regulatory issues underscores the challenges inherent in cross-border pharmaceutical partnerships. The $64 million legal claims looming over this decision highlight the financial and operational risks associated with international collaborations. Meanwhile, biopharmaceutical buyers are increasingly turning to artificial intelligence and local expertise to navigate rising licensing costs in China. Sanofi and Wave Life Sciences are making progress in addressing α1-antitrypsin deficiency (AATD), a genetic disorder that has witnessed limited therapeutic innovation for decades. Their efforts were highlighted at the American Thoracic Society meeting, showcasing ongoing attempts to bridge treatment gaps for rare diseases through next-generation approaches. Strategic investments continue to shape the industry, as evidenced by Lauxera Capital Partners' successful EUR520 million fundraising aimed at advancing healthcare technologies. Additionally, Merck's agreement to supply Keytruda for Exelixis' colorectal cancer trial exemplifies collaborative efforts crucial for advancing cancer research. These developments reflect an industry balancing innovation with regulatory compliance and market dynamics. Scientific progress is also evident in Relay Therapeutics' advancement with its PI3K inhibitor, which has shown promising Phase 2 data in treating blood vessel disorders. This underscores the potential of PI3K inhibitors to address unmet medical needs by targeting pathways significant in cancer and other diseases. The integration of artificial intelligence into drug discovery processes is another critical trend. Incyte's collaboration with Edison Scientific aims to enhance decision-making and streamline drug discovery, showcasing AI's potential to revolutionize R&D efficiency. However, persistent challenges remain as AI scales up but doesn't yet resolve clinical trial protocol issues fully. On the business front, Bristol Myers Squibb considers investing $1 billion in a Houston manufacturing plant, emphasizing strategic infrastructure investments crucial for meeting growing pharmaceutical demands. In drug approvals, AstraZeneca's Baxfendy has received FDA approval for treating uncontrolled hypertension by targeting aldosterone synthesis—offering a novel approach as a combination therapy. Moreover, Merck & Co.'s sacituzumab tirumotecan has achieved Phase 3 success in endometrial cancer trials, demonstrating superior survival outcomes compared to chemotherapy. This highlights the growing impact of targeted therapies in oncology and the ongoing shift towards precision medicine. Despite these positive developments, challenges persist. BioMarin Pharmaceutical's BMN 401 faced setbacks after missing key Phase 3 endpoints for skeletal healing in ENPP1 deficiency patients—highlighting complexities in rare disease drug development. In conclusion, these diverse developments reflect an industry steadfastly committed to advancing healthcare through scientific innovation while navigating regulatory hurdles and operational challenges. As these sectors evolve further, maintaining a balance between rapid innovation and rigorous oversight remains essential to ensuring impactful treatments reach patients worldwide promptly. Thank you for tuning in to Pharma Daily—stay informed and stay ahead of industry trends with us tomorrow!Support the show

FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency's two main review units also left their posts, as did the FDA chief of staff and chief AI officer. Domino effect aside, the reaction from the industry has been mostly positive, given Makary's tumultuous reign. But he might be hard to replace. If it were up to the biotech industry, former longtime oncology regulator and short-lived CDER director Richard Pazdur would take the role. For now, FDA Deputy Commissioner for Food Kyle Diamantas is in charge.Eli Lilly's David Ricks was the highest paid pharma CEO last year, but J&J's Joaquín Duato made the most relative to rank-and-file employees, with a median pay ratio of 358 to one. He was on the top of BioSpace's list last year, too, with a ratio of 293 to 1. Last month, Revolution Medicines' RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. This week, Truist Securities went so far as to nominate RevMed as “the next oncology titan,” a title currently held by Merck and its blockbuster cancer drug Keytruda. Safety continues to challenge the gene therapy space, especially in Duchenne muscular dystrophy. Late last week, REGENXBIO announced mixed results from a Phase 3 program—the gene therapy did lead to functional improvements, but two serious adverse events caused the stock to drop 37%.Finally, Amgen's rare disease drug Tavneos continues to face scrutiny. Last month, the FDA alleged that doctored data were filed to support Tavneos' initial approval. Now, it's been linked to 20 deaths in Japan.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results. A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) underscore a period of uncertainty. With former commissioner Marty Makary stepping down, concerns arise about how these changes might affect drug approvals and regulatory guidance at such a crucial time in the industry. Turning to clinical trials, Regeneron has experienced a setback as its lag-3 inhibitor failed to surpass Merck's Keytruda in phase 3 melanoma studies. This marks Regeneron's second significant late-stage failure within a year, prompting analysts to reassess its strategic direction in oncology. In parallel, Regeneron has inked a $2.3 billion agreement with Parabilis Medicines to develop an advanced antibody-drug conjugate (ADC)-like therapy. The goal is to enhance targeting capabilities by improving binding to complex target sites, which could revolutionize ADC technology. Similarly, BioMarin's substantial investment in Inozyme's enzyme replacement therapy faced hurdles after falling short on one of two primary endpoints in a phase 3 trial for a rare genetic disorder. Such outcomes highlight the inherent risks and high stakes involved in late-stage drug development. Yet, innovation continues to drive progress. Vincentage Pharma's oral GLP-1 agonist has demonstrated a promising mean weight loss of 12.4% over a year, positioning it as a competitor to Eli Lilly's Orforglipron in the burgeoning Chinese market. This reflects the global pursuit to harness GLP-1 receptor agonists in tackling metabolic disorders and obesity. Ipsen has made strides with its long-acting neurotoxin for aesthetic applications, advancing into phase 3 trials following encouraging phase 2 results that showed significant improvements in frown lines lasting up to 24 weeks post-treatment. This progress suggests robust competition against established players like Botox. Meanwhile, Merck and Kelun-Biotech have successfully completed a phase 3 trial with their trop2-directed ADC sacituzumab tirumotecan (SAC-TMT) for endometrial cancer, achieving primary endpoints and paving the way for further regulatory submissions. Such advancements emphasize ADC technology's growing importance in oncology therapeutics. Broad industry trends reflect strategic investments, exemplified by Boston Scientific's $1.5 billion investment in Mirus and an option to acquire its transcatheter aortic valve replacement system—highlighting continued interest in high-growth medtech sectors. In another notable development, Daiichi Sankyo and AstraZeneca have reached a milestone with their ADC Enhertu, securing dual FDA approvals for early breast cancer treatment. These approvals underscore Enhertu's potential to expand treatment options for patients at an early disease stage, potentially altering standard treatment protocols. On the regulatory front, AstraZeneca has secured FDA approval for baxdrostat—an aldosterone synthase inhibitor developed through its acquisition of CinCor Pharma—demonstrating strategic investment in innovative cardiovascular therapies aligned with ambitious revenue goals. However, challenges persist as demonstrated by Amgen's Tavneos being linked to fatalities across Japan and the U.S., raising significant concerns about data integrity and pharmacovigilance. In contrast, Revolution Medicines' RAS inhibitor doubled survival rates in phase 3 pancreatic cancer trials. This breakthrough positions Revolution as an emerging leader in oncology therapeutics amidst fierce competition from companies aiming to improve drug tolerability and extend survival benefits. These narratives paint a picture of an industry poised for transformation—balancing scientific breakthroughs against regulatory challenges and financial pressures. As therapeutic modalities evolve—from oral biologics to advanced ADCs—the sector is set on course for substantial impacts on patient care and drug development pipelines. In summary, the pharmaceutical and biotech industries' focus on advancing therapeutic options through scientific innovation while navigating complex regulatory landscapes underscores an ongoing commitment to addressing unmet medical needs through new drug classes and targeted therapies. These efforts highlight trends toward personalized medicine and precision oncology that are likely to shape future trajectories in these dynamic fields.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show

Welcome to OncLive On Air®! I'm your host today, Riley Kandel.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.During Esophageal Cancer Awareness Month, OncLive® sat down with Peter Enzinger, MD, to discuss evolving standards and ongoing areas of uncertainty in the diagnosis and management of esophageal cancer. In the exclusive interview, Enzinger highlighted common diagnostic and staging pitfalls in newly diagnosed disease; outlined the evolving role of surgery, chemoradiation, and multidisciplinary care; and reviewed emerging targeted therapeutic strategies shaping treatment decisions in esophageal and gastroesophageal cancers. He also discussed ongoing clinical trials of interest, including studies evaluating zanidatamab-hrii (Ziihera), pembrolizumab (Keytruda)–based nonoperative approaches, and novel combinations incorporating Claudin 18.2–targeted therapy.Enzinger serves as director of the Center for Esophageal and Gastric Cancer, institute physician, and medical oncologist at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in Boston, Massachusetts. _____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories and trends shaping the industry. Daiichi Sankyo has unveiled a bold five-year business plan with an eye on rising to become a top-five global oncology leader by 2035. This ambition is driven by a $1.3 billion initiative focused on antibody-drug conjugates, or ADCs, which are targeted cancer therapies. These plans highlight a strategic emphasis on oncology and operational efficiencies designed to maintain competitive advantage in a rapidly evolving market. Meanwhile, CSL Limited faces a more challenging landscape, adjusting its revenue projections and facing a significant impairment related to its acquisition of Vifor Pharma. These financial challenges underline the risks inherent in large-scale acquisitions within the pharmaceutical sector, necessitating a reassessment of strategic priorities and investments in R&D. Regulatory developments continue to be pivotal, with Partner Therapeutics' bispecific antibody Bizengri gaining FDA national priority designation for rare bile duct cancer. This underscores the FDA's dedication to expediting critical therapies through its National Priority Pilot program, aiming to bring life-saving treatments to underserved populations quickly. However, regulatory uncertainty looms with President Donald Trump's reported plan to dismiss FDA Commissioner Marty Makary, which could impact the agency's leadership and agenda. Additionally, a Supreme Court ruling has temporarily reinstated telemedicine access to mifepristone, an abortion pill, spotlighting the ongoing debates about reproductive healthcare accessibility through telemedicine. In research news, Novo Nordisk's collaboration with an AI biotech firm marks a strategic shift aimed at rescuing its Parkinson's cell therapy program. This partnership highlights the increasing role of artificial intelligence in drug development, particularly for revitalizing stalled projects using advanced technological applications. On the clinical trial front, Inhibrx's midphase results are promising for their OX40 agonist combined with Merck's Keytruda, showing doubled response rates in cancer patients. Such advancements underscore the potential of combination therapies in oncology and are likely to draw more investment interest from major players like Merck. Amgen's investment in a quantum technology firm poised for an IPO represents another exciting frontier. The application of quantum computing in drug discovery could revolutionize computational biology by accelerating therapeutic discoveries and improving precision medicine approaches. The biotech sector is also seeing financial maneuvers with quantum tech firms planning IPOs following investments from companies like Amgen. This signals a growing interest in leveraging quantum technology for breakthroughs in drug discovery. In Alzheimer's research, a novel gene therapy study presents an innovative method for clearing amyloid plaques from mouse brains without crossing the blood-brain barrier. By sending a protective gene to the liver, researchers achieved systemic plaque clearance—an approach that could revolutionize treatment strategies if successful in human trials. A new development in diagnostics involves a blood test predicting patient responses to GLP-1 receptor agonists like Ozempic and Wegovy. As these drugs become popular for weight management, such diagnostics could optimize outcomes by identifying patients most likely to benefit. Omada Health reported a 42% revenue increase in Q1, reflecting the expanding digital health solutions market. Their collaboration with Eli Lilly's employer weight loss program indicates rising demand for comprehensive health strategies integrating pharmacotherapy and digital health platforms. Overall, thSupport the show

Quanto vale una vita? È una domanda che nel mondo della farmaceutica ha una risposta precisa, espressa in franchi, euro o dollari. Una scatola di Keytruda, il farmaco oncologico più venduto al mondo, costa in Svizzera oltre quattromila franchi. Ma qual è il costo reale di produzione? Perché, in linea generale, non c'è trasparenza nella definizione dei prezzi dei farmaci? E quale ruolo giocano le lobby del settore? È il tema che affrontiamo in questa puntata di “Laser”, in cui cerchiamo di capire perché non è rispettato il principio di accesso universale alle cure e ai farmaci nel mondo e quali sono le conseguenze per chi resta escluso.Ne parliamo con Patrick Durisch di Public Eye, organizzazione non governativa (ONG) svizzera che si impegna per la giustizia globale e il rispetto dei diritti umani, che ha condotto una stima indipendente dei costi di ricerca e sviluppo del farmaco Keytruda, e con Catherine Moury, professoressa di Scienze Politiche presso la NOVA Università di Lisbona, che ha guidato progetti di ricerca internazionali sulla determinazione dei prezzi dei farmaci.

Quanto vale una vita? È una domanda che nel mondo della farmaceutica ha una risposta precisa, espressa in franchi, euro o dollari. Una scatola di Keytruda, il farmaco oncologico più venduto al mondo, costa in Svizzera oltre quattromila franchi. Ma qual è il costo reale di produzione? Perché, in linea generale, non c'è trasparenza nella definizione dei prezzi dei farmaci? E quale ruolo giocano le lobby del settore? È il tema che affrontiamo in questa puntata di “Laser”, in cui cerchiamo di capire perché non è rispettato il principio di accesso universale alle cure e ai farmaci nel mondo e quali sono le conseguenze per chi resta escluso.Ne parliamo con Patrick Durisch di Public Eye, organizzazione non governativa (ONG) svizzera che si impegna per la giustizia globale e il rispetto dei diritti umani, che ha condotto una stima indipendente dei costi di ricerca e sviluppo del farmaco Keytruda, e con Catherine Moury, professoressa di Scienze Politiche presso la NOVA Università di Lisbona, che ha guidato progetti di ricerca internazionali sulla determinazione dei prezzi dei farmaci.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of localized bladder cancer, covering everything from initial histology to the rapidly evolving treatment paradigms for muscle-invasive disease. Drs Armstrong and Tawagi emphasized that although urothelial carcinoma remains the most common bladder cancer histology, recognizing variants like squamous, adenocarcinoma, and small cell is vital, as they often require surgery-first approaches or specialized chemotherapy. A critical diagnostic pearl highlighted for oncology boards was the necessity of muscularis propria in the transurethral resection of the bladder tumor (TURBT) specimen. If muscle is absent, a repeat TURBT is mandatory to ensure the cancer is not under-staged. For non–muscle-invasive bladder cancer, the treatment goal is preventing recurrence and progression. Patients with high-risk disease should receive BCG induction and maintenance. For those who are BCG unresponsive, Drs Armstrong and Tawagi discussed several novel intravesical therapy options that may be preferred over systemic pembrolizumab to avoid toxicity.The management of muscle-invasive bladder cancer (MIBC) is primarily dictated by cisplatin eligibility, which is determined by performance status, renal function, and the absence of neuropathy or hearing loss. In cisplatin-eligible patients, the phase 3 NIAGARA trial (NCT03732677) results led to a new standard of care (SOC), which is the addition of durvalumab (Imfinzi) to a gemcitabine/cisplatin backbone. Furthermore, the phase 3 KEYNOTE-B15 trial (NCT04700124) data demonstrated that neoadjuvant enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) significantly improved overall survival compared with standard chemotherapy, though this combination is not yet the board-tested standard. For cisplatin-ineligible patients, the phase 3 EV-303 trial (NCT03924895) established neoadjuvant enfortumab vedotin plus pembrolizumab as a new SOC, replacing the previous approach of upfront cystectomy followed by adjuvant nivolumab (Opdivo).Finally, Drs Armstrong and Tawagi discussed trimodal therapy as a bladder-sparing treatment approach. Ideal candidates for this approach must have small tumors, a complete TURBT, no hydronephrosis, and must commit to lifelong cystoscopic surveillance.

Warum nicht einmal das Gesundheitsministerium den Preis jenes Krebs-Mittels kennt, für das Österreichs Spitälern am meisten Geld ausgeben. Stefan Melichar über den Preis von „Keytruda“ und das Projekt  „The Cancer Calculus“ des „ICIJ“.

In this clinically rich episode, host Dr. Ted Lain sits down with board-certified dermatologist and global skin cancer expert Dr. Todd Schlesinger — AAD Board of Directors member, Mohs surgeon, clinical assistant professor at George Washington University School of Medicine, and medical director of the Clinical Research Center of the Carolinas — for a deep dive into systemic and targeted therapies for non-melanoma skin cancer (NMSC). The doctors begin with a thorough breakdown of the hedgehog signaling pathway (PATCHED, Smoothened, GLI-1 transcription) and how mutations in this pathway drive basal cell carcinoma (BCC) growth. They compare the two FDA-approved hedgehog pathway inhibitors (HHIs) — vismodegib (Erivedge) and sonidegib (Odomzo) — covering their mechanisms of action, volume of distribution differences (16–18L vs. ~9,000L), indications for locally advanced and metastatic BCC, how to define "locally advanced," and complete vs. partial response rates. Dosing strategies are addressed in detail, including alternate-day dosing and treatment breaks backed by the MIKIE study and STEVIE safety study. For managing the most common adverse events — muscle cramps, dysgeusia, weight loss, and fatigue — Dr. Schlesinger shares his clinical protocol using L-carnitine supplementation (1,500–2,000mg liquid, started 2–4 weeks before therapy) along with calcium and CoQ10. The conversation then moves to PD-1 and PD-L1 checkpoint inhibitors for locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC) and BCC, covering cemiplimab (Libtayo), pembrolizumab (Keytruda), and nivolumab (Opdivo). The hosts explain the immune checkpoint mechanism using a memorable analogy, discuss how UV exposure upregulates PD-1 on tumor cells, and explore the practical realities of dermatologists prescribing infusion-based immunotherapy — including multidisciplinary care team logistics, buy-and-bill considerations, and when to partner with oncology. The episode closes with an exciting look at the pipeline: intralesional therapies for nodular and superficial BCC from companies including Verica, iViva, PHIO, and Feldan, red light PDT for superficial BCC nearing FDA approval, and the broader question of where these drugs fit as neoadjuvant, adjuvant, or primary therapies — and what complete response benchmarks (80–95%) dermatologists should expect before adopting non-surgical primary options. To watch this and other episodes, be sure to check out our YouTube page DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.See omnystudio.com/listener for privacy information.

While advances in early detection and treatment have reduced cancer deaths in many parts of the world, that progress hasn't reached everyone. In India, cancer cases are rising, with nearly 14 lakh diagnoses in 2022—and access to life-saving drugs remains a major challenge.An investigation by The Indian Express, in collaboration with the International Consortium of Investigative Journalists, reveals how one of the world's leading cancer drugs, Keytruda, remains out of reach for many patients. It also uncovers how gaps in regulation have allowed counterfeit versions of the drug to enter the market.Drawing on over 12,000 documents and records of more than 150 patients, the investigation lays bare the scale of the problem—and its human cost. In this episode, we speak with The Indian Express' Kaunain Sheriff and Anonna Dutt, who led this investigation.Hosted and produced by Shashank BhargavaEdited and mixed by Suresh Pawar

Today, we explain this piece of “clickbait” from our guest!TL;DR: 95% of cancer treatments fail to pass clinical trials, but it may be a matching problem — if we better understood what patients have which tumors which will respond to which treatments, success rates improve dramatically and millions of lives can be saved — with the treatments we ALREADY have.See our full episode dropping today:Why Big Pharma is licensing AI ModelsTolstoy famously wrote, ‘All healthy cells are alike; each cancer cell is unhappy in its own way.' Or something like that. Cancer might be the most misunderstood disease out there. It's not one disease, it's a family of diseases. Hundreds, maybe thousands, of unique diseases each with its own underlying biology. With this lens, saying you'll “cure cancer” is like saying you'll solve legos.We keep hearing AI will cure cancer, but sadly it may not be so easy. Today's guests — Ron Alfa and Daniel Bear from Noetik — thinks they can use AI to break through a core bottleneck in the treatment development process.GSK recently signed a $50M deal for their technology that also includes an (undisclosed) long-term licensing deals for Noetik's models like the recently announced TARIO-2, an autoregressive transformer trained on one of the largest sets of tumor spatial transcriptomics datasets in the world. Whole-plex spatial transcriptomics is the richest way to read a tumor, and approximately ~0% of cancer patients going through standard care ever get one — and TARIO-2 can now predict an ~19,000-gene spatial map from the H&E assay every patient already has. Most big AI plays in BioTech have focused on discovery, and usually result in an in-house development effort (meaning tools companies usually become drug companies). This deal stands out in that it is a software licensing deal, and represents a commitment to a platform rather than a drug. With attention on other software tools for drug development (see the Boltz episode and Isomorphic for example), it is starting to look like the appetite of Pharma for biotech tools has finally started to grow. Why the sudden interest?Cancer is hardBiology is hard, cancer is harder. But despite this, we've made incredible progress. So many cancers that would have been death sentences twenty years ago are routinely survivable. It used to be our main strategy was just chemotherapy — poison you and hope the tumor dies before you do. Now, there are many treatments that actually kill a tumor and leave the rest of you intact! Immune checkpoint inhibitors like Keytruda and Opdivo target the defenses of dozens of tumor types. CAR-T therapy adds modified T-cells to your blood that can target B-cell malignancies very accurately. Antibody Drug Conjugates such as Trastuzumab combine a drug with an antibody, allowing it to target very specific (cancer) cells. We truly live in marvelous times.With that said, we still have a long way to go. For every type of cancer with a miracle treatment, we have many more that are still death sentences. The world spends $20-30 billion a year trying to cure cancers, with hundreds of clinical trials yearly.Yet, progress is slow with a 95% failure rate in clinical trials.The lab doesn't translate to the clinicAre we leaving something on the table? Enter Noetik and Ron Alfa. Ron's core thesis is that many of these “failed” treatments actually work! But we're not looking at the right patients with the right tumors. If only we had a way to really understand the unique types of cancer biologies and which patients will respond to which treatments, we might be able to show a much higher success rate. Millions of lives (and billions of dollars) may ride on this.The Hard part: Blind Faith in Data CollectionRon and Noetik had the conviction to spend almost two years just collecting data. Lots, and lots, and lots, of data. Noetik has acquired thousands of actual human tumors, and collects a large multimodal dataset of hundreds of millions of images that allows them to create a detailed map of the cell makeup in the local environment. These are real human tumors, not frankenstein mouse models or immortal cell lines.This data is then fed into a massive self-supervised model, creating a “virtual cell”. This model has a deep understanding of cancer biology — Noetik has worked carefully to show it can distinguish different types of tumors. Maybe even tumors we didn't identify as distinct previously! More recently they figured out how to scale up their model and data, and see no limit in their scaling laws!Noetik's models can simulate how a patient will respond to experimental treatments. They are working with partners to test promising drugs that were demonstrated to be safe, but not effective. If these models work as hoped, Noetik will bring new cancer treatments to patients without developing a new drug! Their models will also guide the discovery process towards drugs that are more likely to make it through clinical trials. You can imagine why this is so attractive to GSK.We'll see…Ron and Dan make pretty persuasive arguments that their models will truly assist in cohort selection in useful ways and this seems valuable. And we think it's pretty clear that* Translation from lab to clinic is the biggest bottleneck for drug development.* Better cohort selection using biomarkers is likely to improve translation from lab to clinic.Noetik has already had some success here. We'll see if they're able to translate that into a reliable advantage.Stepping back a bit from the technology, curing cancer is a pretty unambiguously positive application of AI. It is also a very hard problem to solve. Our guess is that most people have been impacted by cancer or will be at some point soon. And we hope that learning about the amazing work that companies like Noetik are doing will inspire a generation of AI engineers to work on the hardest and most exciting problems that society faces.Full Video Pod: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

At the 3rd Biennial Miami Precision Medicine Conference, CancerNetwork® spoke with a variety of researchers and clinicians who presented on different topics regarding the use of targeted therapies across several cancer types. Faculty from the University of Miami Sylvester Comprehensive Cancer Center shared key advances and ongoing initiatives across pancreatic cancer, sarcomas, genitourinary malignancies, and other diseases.First, Jashodeep Datta, MD, an associate professor of surgery, a co-leader of the Gastrointestinal Site Disease Group, an associate director of Translational Research, and Sylvester Pancreatic Cancer Research Institute DiMare Family Endowed Chair in Immunotherapy, discussed his presentation on overcoming a historical “moratorium” associated with immunotherapy in pancreatic cancer. Based on recent data, he noted that current goals include analyzing distinct subpopulations of patients who respond to immunotherapy and understanding the biology of why they respond to inform the design of novel therapeutic approaches. Looking towards the future, Datta described how mRNA vaccines may play a larger role in advancing personalized patient care.Next, Steven Bialick, DO, a gastrointestinal and sarcoma and connective tissue medical oncologist, spoke about his presentation on diagnosing and treating patients with sarcomas. He highlighted how markers like microsatellite instability-high status may help identify patients who are suitable candidates to receive immunotherapies like pembrolizumab (Keytruda). Overall, he emphasized the practice of thorough molecular testing to help navigate a treatment landscape that has “changed so dramatically” over the years. Finally, Jaime Merchan, MD, director of the Phase 1 Program and a tenured professor of medicine at the University of Miami Miller School of Medicine, talked about his presentation on the development of novel targeted therapies in genitourinary malignancies, which included bladder and kidney cancers. He described strategies for using new HIF-2⍺ inhibitors alongside therapeutic standards like tyrosine kinase inhibitors. Additionally, he detailed how other investigational drug classes, including oncolytic viruses and T-cell engagers, may fit into the treatment paradigm for these genitourinary cancers. References Datta J. Mission impossible? Strategies for precision immunotherapy in pancreatic cancer. Presented at the 3rd Biennial Miami Precision Medicine Conference; April 11-12, 2026; Fort Lauderdale, FL. Bialick S. Precision oncology in the diagnosis and management of sarcoma patients. Presented at the 3rd Biennial Miami Precision Medicine Conference; April 11-12, 2026; Fort Lauderdale, FL. Merchan J. Genitourinary cancers: bladder and kidney. Presented at the 3rd Biennial Miami Precision Medicine Conference; April 11-12, 2026; Fort Lauderdale, FL.

Hoy en Saga Noticias analizamos los temas que marcan la agenda: las sanciones del gobierno de Estados Unidos contra el Cártel del Noreste y su impacto en la estructura financiera del crimen organizado, junto al especialista en seguridad David Saucedo, quien también aborda la polémica por una presunta persecución política en Tamaulipas. Además, revelamos la investigación de Quinto Elemento Lab con la periodista Violeta Santiago sobre la compra y uso de Keytruda falsificado, un medicamento clave para pacientes con cáncer que exhibe una grave negligencia en el sistema de salud mexicano. En la mesa de análisis, Rosario Robles, Roberto Gil Zuarth y Arturo Maximiliano García debaten la ausencia de la sección “Quién es quién en las mentiras” tras las investigaciones contra Jenaro Villamil, así como los movimientos al interior de Morena, incluida la posible salida de Luisa María Alcalde, y el aumento de la inflación. Finalmente, el activista Arturo Islas confronta el escándalo por el sacrificio masivo de perros en Tecámac, bajo la gestión de la hoy senadora Mariela Gutiérrez. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hoy en Saga Noticias analizamos los temas que marcan la agenda: las sanciones del gobierno de Estados Unidos contra el Cártel del Noreste y su impacto en la estructura financiera del crimen organizado, junto al especialista en seguridad David Saucedo, quien también aborda la polémica por una presunta persecución política en Tamaulipas. Además, revelamos la investigación de Quinto Elemento Lab con la periodista Violeta Santiago sobre la compra y uso de Keytruda falsificado, un medicamento clave para pacientes con cáncer que exhibe una grave negligencia en el sistema de salud mexicano. En la mesa de análisis, Rosario Robles, Roberto Gil Zuarth y Arturo Maximiliano García debaten la ausencia de la sección “Quién es quién en las mentiras” tras las investigaciones contra Jenaro Villamil, así como los movimientos al interior de Morena, incluida la posible salida de Luisa María Alcalde, y el aumento de la inflación. Finalmente, el activista Arturo Islas confronta el escándalo por el sacrificio masivo de perros en Tecámac, bajo la gestión de la hoy senadora Mariela Gutiérrez. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Last December, President Donald Trump convened a meeting of pharmaceutical executives with the goal of getting them to lower the cost of prescription drugs. A few weeks later, one patient battling lung cancer checked into a California clinic for an infusion of Merck & Co.'s blockbuster cancer drug, Keytruda. When the bill arrived, the clinic's charge for a 400 mg dose dominated the page: It was just over $162,000. While Brown only owed about $2,000 herself, the six-figure charges show how quickly prices for cutting-edge medical treatments can balloon in the U.S. health care system. USA TODAY joined the International Consortium of Investigative Journalists in their year-long, reporting effort looking into rising healthcare costs around the world. USA TODAY Health Reporter Ken Alltucker joined The Excerpt to share his insights.Let us know what you think of this episode by sending an email to podcasts@usatoday.com. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Keytruda ist das umsatzstärkste Medikament der Welt und es wirkt auch. Sogenannte Immun-Checkpoint-Inhibitoren retten Leben. Etwa beim schwarzen Hautkrebs und einigen Arten von Lungenkrebs. Das Problem ist also nicht die Wirkung, sondern der Preis. Denn österreichische Spitäler dürfen nicht verraten, wie viel sie für das Medikament zahlen. Eine internationale Recherchegruppe an der auch der STANDARD beteiligt war, hat sich diese Preispolitik einmal genauer angesehen. Die beteiligten Autor:innen Muzayen Al-Youssef und Laurin Lorenz über intransparente Preise, die durch das föderale Österreich noch einmal zu mehr Problem führt.

The government is opening 14 new infusion centres around the country, where patients can get chemotherapy and other therapies. It's also expanding 14 existing infusion centres. The Health Minister said a boost in Pharmac funding that same year is delivering 66 new medicines including 33 cancer treatments, increasing the need for infusions. Triple negative breast cancer survivor, Catherine Cooke, slammed the anouncement saying without medications like Keytruda, funded for early stage cancers, more infusion centres are not the solution and patients are being driven into debt to survive. Cooke spoke to Lisa Owen.

Estados Unidos bloquea el paso a todos los buques que intenten entrar o salir del estrecho de Ormuz, paso crucial para el suministro de energía mundial. Al menos 6 puertos iraníes están bloqueados y se teme un fuerte impacto económico global. El presidente Donald Trump arremetió contra el papa León XIV, quien ha expresado su oposición a la guerra contra Irán. Por su parte el papa asegura que no teme a Trump. El presidente Trump levantó gran controversia al publicar una imagen suya como si fuera Jesucristo curando a un enfermo. Horas después la eliminó de su red social. El representante demócrata Eric Swalwell anunció que renunciará a su curul en el congreso después de varias acusaciones de agresión sexual.

Join Chef AJ's Exclusive Plant-Based Community. Find out more by visiting: https://community.chefaj.com/ ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. To book a consultation with Matt: https://form.jotform.com/241997228318164 Matthew Lederman, MD, is a board-certified Internal Medicine Physician and a pioneering thought leader in holistic health. Renowned for his innovative integration of plant-based nutrition, Nonviolent Communication (NVC), trauma-informed care, and lifestyle medicine, Dr. Lederman's work highlights the profound interconnectedness of physical, emotional, and relational well-being. As a certified Nonviolent Communication Trainer through the Center for Nonviolent Communication (CNVC), Dr. Lederman combines Polyvagal Theory, Somatic Awareness Principles, and Pain Reprocessing to empower individuals to heal from within. His approach helps people address the root causes of chronic health challenges, fostering emotional resilience and cultivating meaningful connections. Dr. Lederman is the co-host of the webe Parents podcast, a platform dedicated to equipping parents with tools and insights to foster emotional connection, resilience, and well-being in their families. His latest book, Wellness to Wonderful, weaves together medical science, psychology, spirituality, and life wisdom to guide individuals toward lasting health, vibrancy, peace, and joy. He is also the co-founder of Kinectin, a platform designed to help individuals build deeper, more fulfilling relationships through AI-driven coaching and personalized assessments. Email (questions & requests): Support@ConnectionDocs.com Website: https://www.connectiondocs.com/ Free Resources (includes Feelings & Needs Sheet for children AND Role-Play Video “Talking to Your Child About ‘Too Much' Device Time”) : https://www.connectiondocs.com/resources Substack (Weekly Articles on Connection): https://substack.com/@connectiondocs Breath & Body Regulation Training Tool: https://webekalm.com/ webe Pärents Podcast https://webekalm.com/pages/webeparents AI Connection Coach:https://app.kinectin.com/signup Main Book WELLNESS TO WONDERFUL: 9 Pillars for Living Healthier, Longer, and with Greater Joy: https://www.amazon.com/dp/B0C2S1JGZK?ref=cm_sw_r_ffobk_cso_sms_apin_dp_K6HM5P02NNK5WAMRGE87&ref_=cm_sw_r_ffobk_cso_sms_apin_dp_K6HM5P02NNK5WAMRGE87&social_share=cm_sw_r_ffobk_cso_sms_apin_dp_K6HM5P02NNK5WAMRGE87&starsLeft=1&skipTwisterOG=1&bestFormat=true Children's E-Books (Supporting Children Bringing More Connection Into Their Lives): Healing Shame and Connecting to Self-Worth and Intrinsic Value: https://webekalm.com/products/lily-and-her-beautiful-flower Being Honest with Care https://webekalm.com/products/ella-and-the-two-gifts-ebook Supporting Children During Emergencies (fires, earthquakes, etc):'https://webekalm.com/products/brave-hearts-facing-the-fire-ebook Social Media: Instagram: https://www.instagram.com/TheConnectionDocs Substack Newsletter: https://connectionDocs.substack.com Facebook: https://www.facebook.com/connectionDocs X: https://x.com/connectionDocs

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Katy Beckermann, MD, to discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium. Dr Beckermann is director of Genitourinary Cancer Research at Tennessee Oncology in Franklin.Their conversation focused on the clinical evolution of HIF-2 targeting, specifically the integration of belzutifan (Welireg) into earlier lines of therapy and novel combinations. Drs. Park and Beckerman examined the phase 3 LITESPARK-022 trial (NCT05239728), which evaluated adjuvant pembrolizumab (Keytruda) plus belzutifan in patients with clear cell renal cell carcinoma (ccRCC). Although the disease-free survival curves showed early and sustained separation, the experts noted that overall survival data remain immature and expressed concern regarding the rate of grade 3 adverse effects with the investigational combination, which may lead to overtreatment in the absence of enrichment biomarkers. However, they noted that a particularly strong efficacy signal was highlighted in the sarcomatoid patient population.In the refractory setting, the phase 3 LITESPARK-011 trial (NCT04586231) comparing lenvatinib (Lenvima) plus belzutifan vs cabozantinib (Cabometyx) in patients with RCC was identified as practice-changing. This investigational combination was shown to increase the median progression-free survival (PFS) and generate durable responses.The discussion also touched on frontline triplet regimens from the phase 1/2 KEYMAKER-U03 umbrella platform. Early data with pembrolizumab plus lenvatinib and belzutifan showed a median PFS that may influence future first-line clinical practice for patients with ccRCC.The experts also emphasized proactive management of unique HIF-2 inhibitor–associated toxicities. They explained that anemia, driven by erythropoietin inhibition, is nearly universal and should be managed with aggressive erythropoietin or darbepoetin supplementation once hemoglobin levels drop below 10 g/dL. Furthermore, they recommended home pulse oximetry to monitor for hypoxia and baseline echocardiograms for TKI combinations to screen for reduced ejection fraction and volume overload.Drs Park and Beckermann concluded by spotlighting the need for familiarity with these new agents to optimize patient outcomes.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.In prostate cancer, the phase 3 PEACE-3 trial (NCT02194842) demonstrated a clear overall survival (OS) benefit with the combination of radium-223 and enzalutamide (Xtandi) compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The phase 2 BRCAAway trial (NCT03012321) showed that for patients with mCRPC with BRCA1/2 or ATM mutations, combination therapy with olaparib (Lynparza) and abiraterone led to a longer median progression-free survival (PFS) than sequential treatment. Additionally, the POSEIDON meta-analysis indicated that short-term hormone therapy is adequate for most patients with prostate cancer receiving postoperative radiotherapy, as longer durations did not improve OS.In bladder cancer, the phase 3 KEYNOTE-B15 trial (NCT04700124) showed that neoadjuvant enfortumab vedotin-ejfv (Padcev) combined with pembrolizumab (Keytruda) significantly improved OS and event-free survival vs neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer, despite notable toxicities like skin and ocular adverse effects. Furthermore, the phase 2 RC48G001 trial (NCT04879329) found that disitamab vedotin (RC48) generated responses in patients with metastatic urothelial carcinoma, including those with HER2-low expression.Regarding renal cell carcinoma (RCC), the phase 3 LITESPARK-011 trial (NCT04586231) showed a PFS benefit with belzutifan plus lenvatinib vs cabozantinib in the second-line setting. In the adjuvant setting, the phase 3 LITESPARK-022 study (NCT05239728) demonstrated that adding belzutifan (Welireg) to pembrolizumab improved disease-free survival vs placebo plus pembrolizumab in patients with resected clear cell RCC.Finally, regarding testicular cancer, a phase 2 trial (NCT04876456) of cabozantinib showed meaningful activity in patients with relapsed/refractory germ cell tumors. Drs Armstrong and Tawagi noted that this marks the first nonchemotherapy agent to demonstrate such clinical benefit in this population, providing a new option for patients who have exhausted traditional treatment regimens.

Astronaut time costs $130,000 per hour, yet a significant portion goes to routine maintenance and cargo logistics rather than breakthrough science. Icarus Robotics is building the robotic workforce for commercial space stations, and despite being just over a year old, secured a deployment partnership with NASA and Voyager Space for the International Space Station in 2027. In this episode, we sat down with Ethan Barajas, CEO and Co-Founder of Icarus Robotics, to understand how they positioned teleoperated robotics as the wedge into a horizontal expansion strategy spanning satellite constellation servicing, space infrastructure maintenance, and eventually cislunar operations.Topics Discussed:Why the shift from NASA-funded ISS to commercial stations fundamentally changes the economics of space laborHow optical communications via Starlink reduced latency from 800ms (S-band radio relay through GEO) to 100ms, enabling Earth-based teleoperationThe teleoperation-to-autonomy data flywheel: collecting in-distribution physics data to train high-level movement primitivesFlight Heritage constraints at NASA and why mainline robotics run on chips that stopped production in the early 2000sCollaborating with commercial station developers during design phase to embed robotic-friendly architecture (hatch tabs, fiducials for localization)Horizontal expansion thesis: ISS labor as the corpus for intelligent robotics across multi-thousand satellite constellations and space infrastructureThe biological research unlock: how Keytruda's $25B revenue between 2023-2024 resulted from ISS protein crystallization researchGTM Lessons For B2B Founders:Time market entry to structural cost shiftsStack infrastructure betsBuild the data moat earlyInfluence infrastructure design earlyFrame automation as economic inevitabilityUse distribution to attract technical talentPlan horizontal expansion early// Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.ioThe Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co//Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Susana M. Campos, MD, MPH. Dr Campos is the clinical director and director of Educational Initiatives for the of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, and an institute physician and assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. Drs Matulonis and Campos discussed the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.According to 2026 estimates from the American Cancer Society, approximately 13,400 new cases of invasive cervical cancer will be diagnosed in the United States, with roughly 4200 deaths. Although incidence has declined over time due to human papillomavirus (HPV) vaccination and screening efforts, rates have plateaued, and the disease burden remains substantial, particularly among women aged 35 to 64 years. Dr Campos noted that approximately half of cases occur in women younger than 50 years of age, and about 20% are diagnosed in women older than 65 years of age.Dr Campos reviewed common presenting symptoms, including abnormal vaginal bleeding, intermenstrual or postmenopausal bleeding, abnormal discharge, pelvic pain, and, in advanced cases, urinary symptoms or leg swelling. She explained that diagnosis begins with pelvic examination and cervical cytology or HPV testing, followed by colposcopy and biopsy when indicated. Although cervical cancer remains one of the few malignancies that is clinically staged, imaging modalities, such as MRI, CT, and PET scans, are critical to accurately defining disease extent, they underscored. Moreover, the discussion highlighted transformative advances in locally advanced disease. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated improved progression-free and overall survival with the addition of pembrolizumab (Keytruda) to standard chemoradiation, establishing a new standard for high-risk patients, Campos stated. Similarly, the phase 3 INTERLACE trial (NCT01566240) showed that short-course induction chemotherapy with carboplatin and paclitaxel before chemoradiation improved long-term outcomes. Campos forecasted that ongoing studies, including the phase 3 NRG-GY037 trial (NCT07061977), may integrate these approaches and further refine optimal treatment sequencing.Lastly, Drs Matulonis and Campos highlighted the expanding therapeutic arsenal in the recurrent and metastatic setting. Campos noted how antibody-drug conjugates, such as tisotumab vedotin-tftv (Tivdak) and fam-trastuzumab deruxtecan-nxki (Enhertu), have demonstrated meaningful activity, particularly in biomarker-selected populations. Campos added that investigational strategies targeting TROP2, such as sacituzumab govitecan-hziy (Trodelvy), represent additional promising avenues.Despite these advances, both experts emphasized that prevention remains paramount. Widespread uptake of HPV vaccination, including the 9-valent vaccine, as well as adherence to routine cervical screening, are essential to reducing the long-term burden of this largely preventable disease.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium, noting presentations to watch at sessions on prostate cancer, bladder cancer, and renal cell carcinoma (RCC).For prostate cancer, the experts revealed that they're looking forward to seeing updated results from the phase 3 PEACE-3 trial (NCT02194842) of enzalutamide (Xtandi) plus radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), noting that bone-protecting agents are mandatory for patients receiving radium-223. They also pointed to overall survival data from the phase 2 BRCAAway trial (NCT03012321) of abiraterone (Zytiga) plus prednisone and olaparib (Lynparza) for patients with mCRPC harboring BRCA or ATM alterations. Additionally, they spotlighted the phase 3 PEACE 2 trial (NCT01952223), which explores moving chemotherapy into the localized prostate cancer setting.Regarding bladder cancer, they identified the phase 3 KEYNOTE-B15 trial (NCT04700124) as a potentially practice-changing trial evaluating perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in cisplatin-eligible patients with muscle-invasive bladder cancer. They also noted that circulating tumor DNA data are a significant trend, appearing in several clinical trials to guide response-adapted management.For RCC, the hosts highlighted the phase 3 LITESPARK-011 (NCT04586231) and LITESPARK-022 (NCT05239728) trials, which are evaluating the HIF-2α inhibitor belzutifan (Welireg) in different RCC populations. They also emphasized the importance of the CLIMATE study (ACTRN12622000247774) for detecting residual disease in patients with testicular cancer.